Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Which treatment works better for Meibomian Gland Dysfunction: LipiFlow or intense pulsed light? A systematic review and network meta-analysis

While both IPL and LipiFlow showed improvements over controls in treating MGD, there is currently no direct comparative evidence between these modalities.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors reviewed 12 randomized trials of intense pulsed light or LipiFlow thermal pulsation for meibomian gland dysfunction, involving 969 patients. Both treatments improved outcomes compared with controls, but no trial compared them directly, so the authors report that any ranking of the two relies on indirect comparisons and should be interpreted cautiously.

Participants
969
Studies included
12
Who or what was studied
Patients with meibomian gland dysfunction (evaporative dry eye disease) enrolled in randomized controlled trials of intense pulsed light or LipiFlow.
Limits stated in the abstract
None of the included studies compared LipiFlow directly with intense pulsed light, control interventions varied widely, and the indirect comparisons carry substantial heterogeneity.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Meibomian Gland Dysfunction (MGD) is a common cause of evaporative dry eye disease. Intense Pulsed Light (IPL) and LipiFlow thermal pulsation are two device-based treatment modalities currently used for managing MGD. This systematic review and meta-analysis aimed to assess and compare the efficacy of these interventions. It is important to underscore that none of the 12 studies included in this review directly compare LipiFlow with IPL, making indirect comparisons necessary.

Methods

We systematically searched PubMed, Google Scholar, and ScienceDirect for randomized controlled trials (RCTs) assessing either IPL or LipiFlow for MGD, published up to February 2025. Study quality was appraised using the Cochrane Risk of Bias (RoB 2) tool. A random-effects meta-analysis was conducted for primary outcomes including TBUT (tear breakup time), SPEED (Standard Patient Evaluation of Eye Dryness) score, and OSDI (Ocular Surface Disease Index). A Bayesian network meta-analysis (NMA) was performed to enable indirect comparison between IPL and LipiFlow.

Results

Twelve RCTs involving 969 patients (1938 eyes) were included. Six studies assessed LipiFlow and six assessed IPL, but none provided a head-to-head comparison. LipiFlow significantly improved TBUT (MD: +0.67s; 95% CI: [0.08, 1.26], p=0.03) and reduced OSDI scores (MD: -6.07; 95% CI: [-10.85, -1.29], p=0.01), though changes in SPEED score were not statistically significant (p=0.15). IPL demonstrated superior efficacy in increasing TBUT (MD: +2.08s; 95% CI: [0.39, 3.71], p=0.02) and reducing SPEED scores (MD: -2.9; 95% CI: [-5.18, -0.64], p=0.01), while OSDI results were not significant. Control groups across studies varied greatly, ranging from untreated controls to warm compresses, eyelid hygiene, or mechanical expression, further complicating cross-study comparisons. However, these conclusions are based solely on indirect comparisons, which should be interpreted cautiously given the absence of head-to-head studies and the heterogeneity of control interventions.

Conclusions

While both IPL and LipiFlow showed improvements over controls in treating MGD, there is currently no direct comparative evidence between these modalities. As a result, any comparative conclusions must be interpreted with caution. The variability in control group interventions across studies (e.g., untreated vs. warm compresses or eyelid hygiene) introduces significant heterogeneity, reducing the certainty of indirect comparisons. Direct head-to-head RCTs are urgently needed to establish the relative efficacy of these interventions. SYSTEMATIC REVIEW

Registration

PROSPERO

Registration Number

CRD42024543448.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Meta-analysis, Systematic review, Heterogeneity, Control group, Risk of bias, Dry eye. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies